Skip to content

Author

Rachel A. Pearson

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Does a Magnetic Resonance-Only Pathway Impact Dosimetric and Acute Clinical Outcomes in Prostate Stereotactic Ablative Body Radiotherapy?

AIMS This study aimed to compare prostate target and organs at risk (OAR) volumes, doses, and acute toxicity scores for patients treated with prostate stereotactic ablative body radiotherapy (SABR) using magnetic resonance (MR)-only or MR registered with computed tomography (MR-CT) pathways. MATERIALS AND METHODS A t...

J. Wyatt, April Eassom, Serena West et al. · 0 citations
Open access Oct 2026

EPIC-A: Phase II Trial of Cemiplimab Plus Standard-of-Care Chemotherapy Followed by Maintenance Cemiplimab in Locally Advanced or Metastatic Penile Carcinoma

Cisplatin-based combination chemotherapy is standard of care (SoC) for patients with locally advanced/metastatic penile cancer (la/mPC). We evaluated efficacy and safety of cemiplimab plus SoC chemotherapy as first-line treatment in these patients. In this phase II, single-arm, multicenter trial, patients...

A. Challapalli, B. Venugopal, M. Afshar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.